Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden ABSUSRF 84 Cash-to-Debt is 230.45 as of Jun. 2026, which is 38% below its 10-year median of 371.18. GuruFocus rates SUSRF with a GF Score™ of 84/100 and a GF Value™ of $19.51 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 673 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 93.16% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Surgical Science Sweden AB's cash to debt ratio for the quarter that ended in Jun. 2026 was 230.45.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Surgical Science Sweden ABcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Surgical Science Sweden AB's Cash-to-Debt or its related term are showing as below:
SUSRF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: 371.18 Max: No Debt
Current: 230.45
During the past 12 years, Surgical Science Sweden AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.06. And the median was 371.18.
SUSRF's Cash-to-Debt is ranked better than 93.16% of 673
companies
in the Healthcare Providers & Services industry
Industry Median: 0.78
vs SUSRF: 230.45
Surgical Science Sweden AB (OTCPK:SUSRF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Surgical Science Sweden AB Cash-to-Debt Related Terms
Surgical Science Sweden AB Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Health Information Services subindustry, Surgical Science Sweden AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (SUSRF) has a Cash-to-Debt of 230.45 as of Jun. 2026. This is 38% below median its historical median of 371.18. Over the past decade, Surgical Science Sweden AB's Cash-to-Debt has ranged from 0.06 to 10,000.00. According to the industry distribution chart, Surgical Science Sweden AB ranks #46 out of 673 companies in the Healthcare Providers & Services industry, placing it in the top 6.8%.
Is Surgical Science Sweden AB's Cash-to-Debt too high?
Surgical Science Sweden AB's current Cash-to-Debt of 230.45 is 38% below median its 10-year median of 371.18. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 10,000.00. The Healthcare Providers & Services industry median Cash-to-Debt is 0.78. Surgical Science Sweden AB's value of 230.45 is 29444.9% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #46 out of 673 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Surgical Science Sweden AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Cash-to-Debt compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #46 out of 673 companies for Cash-to-Debt. This places Surgical Science Sweden AB in the top 7% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.78. Surgical Science Sweden AB's value of 230.45 is 29444.9% above this benchmark. Historically, Surgical Science Sweden AB's own Cash-to-Debt has ranged from 0.06 to 10,000.00 over the past decade. While the company's 10-year median is 371.18 vs. the industry median of 0.78, Surgical Science Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.78, based on 673 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Cash-to-Debt of 230.45 is 29444.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Cash-to-Debt is 230.45, which is 38% below median its own 10-year median of 371.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $19.51, compared to a current price of $5.20 — trading 73.3% below its estimated fair value. The current Cash-to-Debt is 230.45, which is 38% below median its 10-year median of 371.18 and 29444.9% above the Healthcare Providers & Services industry median of 0.78. Surgical Science Sweden AB's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Cash-to-Debt is 230.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $5.20 is trading 73.3% below its estimated GF Value™ of $19.51.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Cash-to-Debt: 230.45 (38% below median its 10-year median of 371.18)
GF Value™: $19.51 vs. price of $5.20 (73.3% below fair value)
Industry Position: 29444.9% above the Healthcare Providers & Services median (#46 of 673)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
84GF Score
Get the complete analysis for SUSRF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
